The IMPROVE study--a multinational, multicentre, observational study in type 2 XXXX : results from the Italian cohort.

@entity1 @entity413 @entity14184 @entity6
AIMS: The IMPROVE study evaluated the safety and effectiveness of biphasic insulin aspart 30/70 ( @entity14184 ) in type 2 @entity6 @entity1 in the routine practice. Here we present the results for @entity1 from Italy. METHODS: Adverse events, hypoglycaemia, glycaemic control, @entity1 treatment satisfaction and physician resource utilisation were assessed at baseline and 26 weeks. RESULTS: Out of the 1371 @entity1 enrolled, 84.1% (n=1153) were receiving @entity14184 at baseline (in accordance with local regulations), and were included in the study. Mean HlbA, reduction was--0.63% after 26 weeks (p < 0.001); 26.5% and 13.5% of @entity1 reached the HbA(1c) targets of < 7% and < 6.5%, respectively. Fasting and postprandial blood @entity413 significantly decreased; 65% of @entity1 were using @entity14184 once daily and 32% twice daily at final visit. Rates of major and minor hypoglycaemic events also significantly decreased. Small weight increase was observed, and total insulin daily dose increased from 0.29 IU/kg pre-study to 0.32 IU/kg at final visit. CONCLUSIONS: In Italy, @entity14184 in the routine care improved glycaemic control and reduced hypoglycaemia; however, there was little intensification and titration. This may partly explain the relatively small improvement in glycaemic control in Italy compared with other countries in the IMPROVE study.
